Sign in
4

Changes in Ownership

Oncotelic Therapeutics, Inc. Filed Acc 0001209191-17-003702

Options or other derivatives

  • Chief Financial Officer acquired 350,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
LOAR MATTHEW M Chief Financial Officer 2017-01-12 Grant or award · Employee Stock Option (Right to Buy) +350,000 $0.38 $131,250 350,000 D
Loading xslF345X03/doc4.xml…